CA-USERTESTING
26.7.2022 09:02:12 CEST | Business Wire | Press release
UserTesting (NYSE: USER), a leader in video-based human insight , today announced that UserTesting CEO Andy MacMillan will be joining host Nick Murray, Co-Director Startup Grind Scotland and Strategic Partnerships Manager, Metanomic, for a discussion focused on topics that include empathy in leadership, and what makes Edinburgh an ideal location as a European headquarters for technology companies. This event is taking place on Thursday, August 4, at UserTesting’s European headquarters in Edinburgh.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220726005085/en/
Attendees also can hear what Scotland can learn from Silicon Valley’s mindset, the value of customer insights in helping to drive business decisions during challenging economic periods, and lessons learned from rapidly growing a SaaS company through an IPO.
Discussion Details:
- Date: Thursday, August 4, 2022
- Time: 6:00 p.m. to 9:00 p.m., BST
- Location: UserTesting EMEA Headquarters, 2nd Floor, 7 Exchange Crescent, Edinburgh, EH3 8AN
- Cost: 6 GBP public, Free for UserTesting team members (prior registration required)
-
Speakers:
- Andy MacMillan, CEO of UserTesting
- Nick Murray, Host and Co-Director Startup Grind Scotland
"Community gatherings with globally-proven industry experts are critical to developing Scotland's entrepreneurial ecosystem," said Nick Murray, Co-Director of Startup Grind Scotland. "Our first interview with Andy in Silicon Valley this April was a significant mindset shift for the 20 Scottish founders we took to the entrepreneurship mecca. With the Scottish Government announcing Scotland's Tech Scaler Hubs this month, now is the perfect time to look internationally to find best practices and learn from those who have been there before. This interview will broaden the horizons of what's possible for Scottish businesses through the eyes of someone who has had incredible success in scaling a SAAS business to a global entity."
“Selecting Edinburgh was the right choice for UserTesting’s European headquarters, and we are excited to be a part of this event, highlighting the value we have found in establishing offices here,” said Andy MacMillan, CEO of UserTesting. “UserTesting is proud to support Edinburgh’s, and Scotland’s, growing technology scene. There are great opportunities for companies in Scotland, due to the local education system, partnership opportunities with local government agencies, and the local talent, which is what global technology companies are looking for today.”
About UserTesting
UserTesting (NYSE: USER) has fundamentally changed the way organizations get insights from customers with fast, opt-in feedback and experience capture technology. The UserTesting Human Insight Platform taps into our global network of real people and generates video-based recorded experiences, so anyone in an organization can directly ask questions, hear what users say, see what they mean, and understand what it’s actually like to be a customer. Unlike approaches that track user behavior then try to infer what that behavior means, UserTesting reduces guesswork and brings customer experience data to life with human insight. UserTesting has approximately 2,500 customers, including more than half of the world’s top 100 most valuable brands according to Forbes. UserTesting is headquartered in San Francisco, California. To learn more, visit www.usertesting.com
.
About Startup Grind Scotland
Startup Grind is the world's largest community of startups, founders, innovators, and creators based in 125+ countries with 600 chapters worldwide. Startup Grind Scotland is committed to supporting Scotland's vibrant entrepreneurial community, hosting fireside chats and panel conversations with some of Scotland's most influential and exciting business leaders. Past speakers include Mark Logan (Scotland's Chief Entrepreneur and ex-Skyscanner COO), Darina Garland (co-founder, Ooni) and Evelyn McDonald (CEO, Scottish EDGE).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220726005085/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom